title: Effects of dose and route of administration on pharmacokinetics of (+ or -)-3,4-methylenedioxymethamphetamine in the rat.
abstract: Based on animal data, there is speculation that (+ or -)-3,4-methylenedioxymethamphetamine (MDMA) is neurotoxic to humans. Extrapolation of MDMA findings from animals to humans requires assessment of pharmacokinetics in various species, and low-dose administration data from rats are lacking. In this study, we examine MDMA pharmacokinetics in rats given low (2 mg/kg) and high (10 mg/kg) doses of racemic MDMA via intraperitoneal, subcutaneous, and oral routes. Repeated blood specimens were collected from venous catheters, and plasma was assayed for MDMA and its metabolites, 4-hydroxy-3-methoxymethamphetamine (HMMA) and 3,4-methylenedioxyamphetamine (MDA), by gas chromatography-mass spectrometry. After 2 mg/kg, maximum MDMA concentrations (C(max)) were approximately 200 ng/ml for intraperitoneal and subcutaneous routes, but less for the oral route. MDMA plasma half-lives were <1 h for low-dose groups, whereas HMMA and MDA half-lives were >2 h. After 10 mg/kg, MDMA areas under the curve (AUCs) were 21-fold (intraperitoneal), 10-fold (subcutaneous), and 36-fold (oral) greater than those at 2 mg/kg. In contrast, HMMA AUC values in high-dose groups were <3-fold above those at 2 mg/kg. Several new findings emerge from this report of low-dose MDMA pharmacokinetics in rats. First, 2 mg/kg MDMA in rats can produce MDMA C(max) values similar to those in humans, perhaps explaining why both species discriminate 1.5 mg/kg MDMA in laboratory paradigms. Second, our data provide additional support for nonlinear kinetics of MDMA in rats, and, analogous to humans, this phenomenon appears to involve impaired drug metabolism. Finally, given key similarities between MDMA pharmacokinetics in rats and humans, data from rats may be clinically relevant when appropriate dosing conditions are used.
authors.affiliation: Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, 333 Cassell Dr., Suite 4500, Baltimore, MD 21224, USA. mbaumann@mail.nih.gov
authors.forename: Michael H
authors.initials: MH
authors.lastname: Baumann
authors.forename: Dorota
authors.initials: D
authors.lastname: Zolkowska
authors.forename: Insook
authors.initials: I
authors.lastname: Kim
authors.forename: Karl B
authors.initials: KB
authors.lastname: Scheidweiler
authors.forename: Richard B
authors.initials: RB
authors.lastname: Rothman
authors.forename: Marilyn A
authors.initials: MA
authors.lastname: Huestis
mesh_terms: D000818:Animals; D004305:Dose-Response Relationship, Drug; D004333:Drug Administration Routes; D008297:Male; D008657:Metabolic Clearance Rate / Q000187:drug effects / Q000502:physiology; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000008:administration & dosage* / Q000031:analogs & derivatives / Q000493:pharmacokinetics*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014018:Tissue Distribution / Q000187:drug effects / Q000502:physiology
chemical_list: D018817:N-Methyl-3,4-methylenedioxyamphetamine
references.citation: Chem Res Toxicol. 2001 Sep;14(9):1203-8
references.pmid: 11559034
references.citation: Neuroscience. 2008 Mar 27;152(3):773-84
references.pmid: 18313226
references.citation: Ther Drug Monit. 2004 Apr;26(2):132-6
references.pmid: 15228153
references.citation: Drug Metab Dispos. 2007 Oct;35(10):1840-5
references.pmid: 17640955
references.citation: Am J Cardiol. 2007 Nov 1;100(9):1442-5
references.pmid: 17950805
references.citation: Ther Drug Monit. 2004 Apr;26(2):137-44
references.pmid: 15228154
references.citation: J Clin Psychopharmacol. 2008 Aug;28(4):432-40
references.pmid: 18626271
references.citation: Environ Toxicol Pharmacol. 1999 Jul;7(3):153-8
references.pmid: 21781921
references.citation: Drug Metab Dispos. 2009 Oct;37(10):2079-86
references.pmid: 19628751
references.citation: J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Dec 15;876(2):266-76
references.pmid: 19026602
references.citation: Biochem Pharmacol. 1994 Mar 29;47(7):1151-6
references.pmid: 7909223
references.citation: Drug Alcohol Depend. 2006 Jan 4;81(1):27-36
references.pmid: 15975736
references.citation: J Pharm Sci. 2008 Apr;97(4):1593-605
references.pmid: 17724664
references.citation: J Pharmacol Exp Ther. 1999 Jul;290(1):136-45
references.pmid: 10381769
references.citation: Ther Drug Monit. 2009 Jun;31(3):367-73
references.pmid: 19417716
references.citation: J Psychopharmacol. 2005 Jan;19(1):71-83
references.pmid: 15671132
references.citation: Ther Drug Monit. 2008 Jun;30(3):320-32
references.pmid: 18520604
references.citation: Neuropsychobiology. 2000;42(1):5-10
references.pmid: 10867550
references.citation: Psychopharmacology (Berl). 2008 Apr;197(2):263-78
references.pmid: 18074122
references.citation: J Anal Toxicol. 2007 Apr;31(3):138-43
references.pmid: 17579960
references.citation: Mol Pharmacol. 1994 Feb;45(2):359-65
references.pmid: 7906857
references.citation: Trends Pharmacol Sci. 2004 Oct;25(10):505-8
references.pmid: 15380932
references.citation: J Pharm Biomed Anal. 1992 Sep;10(9):657-65
references.pmid: 1363061
references.citation: Addiction. 2002 Dec;97(12):1531-6
references.pmid: 12472637
references.citation: Eur J Pharmacol. 1986 Dec 16;132(2-3):269-76
references.pmid: 2880735
references.citation: Pharmacol Biochem Behav. 1988 Dec;31(4):817-24
references.pmid: 2908067
references.citation: Psychopharmacology (Berl). 2009 Jun;204(2):375-8
references.pmid: 19139850
references.citation: Life Sci. 1986 Oct 20;39(16):1457-64
references.pmid: 2877380
references.citation: Psychopharmacology (Berl). 2007 Jan;189(4):489-503
references.pmid: 16220332
references.citation: Biochem Pharmacol. 1996 Mar 22;51(6):789-96
references.pmid: 8602874
references.citation: Eur J Pharmacol. 1991 Jul 23;200(1):9-16
references.pmid: 1685125
references.citation: Psychopharmacology (Berl). 2007 Jan;189(4):407-24
references.pmid: 16541247
references.citation: Biochem Pharmacol. 1997 Jun 1;53(11):1605-12
references.pmid: 9264312
references.citation: Br J Clin Pharmacol. 2000 Feb;49(2):104-9
references.pmid: 10671903
references.citation: Mol Pharmacol. 2003 Jun;63(6):1223-9
references.pmid: 12761331
references.citation: Ann N Y Acad Sci. 2008 Oct;1139:151-63
references.pmid: 18991859
references.citation: Neurotoxicology. 1989 Fall;10(3):529-42
references.pmid: 2576304
references.citation: J Pharmacol Exp Ther. 2008 Oct;327(1):38-44
references.pmid: 18591215
references.citation: Toxicol Lett. 2000 Mar 15;112-113:133-42
references.pmid: 10720722
references.citation: Pharmacol Rev. 2003 Sep;55(3):463-508
references.pmid: 12869661